Bispecific antibody · Immune activation, directed at programmed cell death protein 1 (PDCD1) and transforming growth factor beta receptor II (TGFBR2) · developed by Incyte
INCA33890 is a bispecific antibody that binds PD-1 and TGF-beta receptor II (TGFbRII). Binding PD-1 blocks its activation by PD-L1 and PD-L2, and binding TGFbRII blocks TGF-beta from engaging it, relieving T-cell and NK cell suppression in the tumor microenvironment. It is being studied in colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07284849 | Phase 3 | CRC (Colorectal Cancer) | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CRC (Colorectal Cancer)
Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →